Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care.
Show moreShow less
Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin.
It has collaborations with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Race Oncology Ltd and changed its name to Racura Oncology Ltd in December 2025.
Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Quality Score breakdown
Overall quality37/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability0
How much profit the company makes from its sales and capital
Quality Growth30
Are margins and returns getting better?
Cashflow5
Do the profits arrive as real cash?
Financial strength98
Debt, balance sheet and risk of trouble
Investment58
Does it invest with discipline instead of growing at any price?
Low Volatility34
How calm the share price moves, does not count
Price momentum6
Price momentum of the last 3 to 12 months, does not count
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+51.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+104.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+106.9%
Start year 2020 (pandemic). Over 10 years: +156.5% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.4%
’13
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,484.8% (2020) → −62.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 562 stocks
Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Below median
Profitability
Return on assets−29.1% · Below median
Net margin (12 months)−79.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−12.2% · Bottom 25%
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
Race Oncology Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Race Oncology Ltd (RAC)?
Race Oncology Ltd reported trailing-twelve-month revenue of about A$2.8M (latest available figure, as of Nov 4, 2026).
How solid is the balance sheet of Race Oncology Ltd (RAC)?
Balance-sheet figures for Race Oncology Ltd (as of Nov 4, 2026): return on equity −42.3%, debt of 0.14 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
Which stocks are comparable to Race Oncology Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Race Oncology Ltd (RAC)?
The closing price on Nov 5, 2026 was A$1.48. We carry closing prices from our data provider, not a live tick.
Key figures of Race Oncology Ltd
How large is the market capitalisation of Race Oncology Ltd (RAC)?
The market capitalisation of Race Oncology Ltd is A$291M (≈ $204M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Race Oncology Ltd (RAC)?
Earnings per share at Race Oncology Ltd are A$−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Race Oncology Ltd (RAC)?
The return on equity (ROE) of Race Oncology Ltd is −42.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Race Oncology Ltd (RAC)?
On an EBIT basis the return on assets of Race Oncology Ltd is −44.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Race Oncology Ltd (RAC)?
The operating margin of Race Oncology Ltd is −370% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Race Oncology Ltd (RAC)?
Revenue at Race Oncology Ltd is growing −12.2% versus a year earlier (3y avg +104%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Race Oncology Ltd (RAC) generate?
The free cash flow of Race Oncology Ltd is −A$8.3M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Race Oncology Ltd (RAC) hold?
Race Oncology Ltd holds more cash than debt, A$34.3M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Race Oncology Ltd in the live analysis
One click puts Race Oncology Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026